Business Overview and Strategy
Management described Arvaya as a technology-led healthcare company founded on the premise of using data and technology to deliver better healthcare at an affordable cost. The company's core strategy involves creating a lifetime digital health record for patients (a "digital health briefcase") and developing an AI-powered clinical intelligence engine to support clinical decisions. The long-term vision is to build an integrated Health Managed Organization (HMO) inspired by the Kaiser Permanente model, excluding the insurance component.
The company's three key building blocks are:
1. Hospitals: Delivery channel through SeCURE Hospitals, a 100% subsidiary.
2. ArvayaSecure App: A patient app for health records, appointments, teleconsultation, diagnostics, and pharmacy.
3. Clinical Intelligence Engine (SecurANT): An AI engine to turn medical records into structured data and support doctor decisions.
Operational Performance (Q2 & H1 FY27)
Capacity & Utilization:
- Operational beds stood at 517 as of September 2026, up from 262 a year ago.
- Overall occupancy was 38% (Q2 FY27), compared to 48% a year ago. The decline is attributed to the near-doubling of the bed base, with established hospitals running at 46% occupancy and newer hospitals at 27%.
- Patient discharges grew 38% year-on-year to 5,526 in Q2 FY27.
- Outpatient (OPD) visits increased to 35,429 in Q2 FY27 from 33,500 previously.
- Average Revenue Per Occupied Bed (ARPOB) rose approximately 17% year-on-year to ₹23,651, driven by a richer case mix in specialties like cardiology, neurosciences, kidney, and robotic surgery.
Hospital Specifics:
- Hubballi (flagship, 135 beds across two units) ran at 56.5% occupancy in H1.
- Mysuru-II hospital, added in August, has the highest ARPOB at ₹31,000.
- Kolhapur hospital broke even in its first month of operation.
- The company follows an asset-light model, with all operating units except Gadag being leased.
Financial Performance
Q2 FY27 Financials:
- Revenue: ₹40 Crore, up 35% quarter-on-quarter (QoQ).
- EBITDA: ₹5.24 Crore, up 32% QoQ.
- EBITDA Margin: 13.0% (vs. 13.1% in Q1 FY27).
- Profit After Tax (PAT): ₹1.37 Crore, up from ₹0.53 Crore in Q1 FY27 (158% growth QoQ).
- Earnings Per Share (EPS): ₹0.25.
H1 FY27 Financials:
- Revenue: ₹70.19 Crore.
- EBITDA: ₹9.21 Crore.
- EBITDA Margin: 13.1%.
- Profit After Tax (PAT): ₹1.9 Crore.
Balance Sheet & Cash Flow (as of September 30, 2026):
- Equity: ₹63.96 Crore.
- Borrowings: ₹31.34 Crore.
- Cash: ₹2.8 Crore.
- Net Debt: ₹28.54 Crore (approx. 0.45x equity).
- Operating Cash Flow (H1): ₹8.6 Crore (89% of EBITDA).
Expansion and Growth Plans
Near-term Capacity:
- The company expects to have 791 operational beds by December 2026. This includes the integration of Sushodha Institute of Gastroenterology (SIGPL), effective November 1, 2026.
- Of the 791 beds, 517 are currently operating, meaning 274 beds are under fit-outs and expected to be operational in Q3 FY27.
Signed Pipeline:
- MoUs signed for 220 beds in Jalna, Sangli, and Shivamogga, due to be operational by the end of FY28.
Long-term Target:
- Targeting 2,400 beds by FY30 through operating partnerships and acquisitions.
Recent Acquisition - Sushodha Institute of Gastroenterology (SIGPL):
- Acquired via a 100% share swap deal with no cash payout.
- It is a super-specialty gastroenterology unit.
- Current run rate: ~₹1 Crore monthly revenue.
- Expected profitability: ~15-18%.
- Expected contribution by March 2027: ~₹5 Crore turnover and ~₹70-80 Lakh profit.
Technology Initiatives
ArvayaSecure App:
- The patient engagement app is scheduled to be launched in the current financial year (FY27).
- 30,000 historical patient records have already been ingested and are enabled on the platform.
- The app will be fully deployed across the SeCURE network by next quarter (Q3 FY27).
Clinical Intelligence Engine (SecurANT):
- The AI engine is at the pilot stage and is already working on the 30,000 ingested patient records.
- Built on global FHIR standards.
Funding for Tech: A proposed rights issue of ₹206 Crore includes an earmarked ₹4.5 Crore for further development of SecurANT. Annual running costs are estimated at ₹2-3 Crore.
Future Business Lines
Management expressed intent to build a diagnostic network (labs and home collection services) and radiology services to feed data into their technology platform and support the HMO vision. A formal plan is expected to be discussed next quarter.
Capital Expenditure & Funding
Capex Model: A new 100-bed hospital in a leased building costs approx. ₹23.6 Crore to set up and is planned to break even in 1.5-2 years.
Rights Issue: The company has filed for a rights issue of ₹206 Crore to fund new medical equipment, fit-outs, and planned acquisitions.
Guidance and Outlook
- EBITDA margins are expected to be sustainable in the range of 13-14% going forward.
- The company aims to hold EBITDA broadly at current levels during expansion, as new beds are expected to reach breakeven over a short period.
Other Key Disclosures
Goa Resort: The property is being repurposed for wellness, with current occupancy being negligible. Work is ongoing, and details on occupancy and margins (expected 15-20%) are anticipated next quarter.
Government Schemes: Revenue from schemes like Ayushman Bharat constitutes 15-20% of the mix. They aid in utilization but are less profitable than private payers.
Geographic Focus: The company will initially focus on saturating 12-15 core districts in Karnataka and Maharashtra to build a concentrated regional network essential for its HMO model before expanding to other regions.
Data Security: The technology architecture is built to be compliant with global standards like HIPAA and India's DPDP Act from the ground up.